Javad Nazarian
About Javad Nazarian
Javad Nazarian is an Associate Professor of Genomics and Precision Medicine at The George Washington University School of Medicine and Health Sciences, where he has worked since 2009. He specializes in cancer research, particularly focusing on childhood brain tumors and has developed one of the largest biobanks of DIPG tissue samples.
Work at The George Washington University
Javad Nazarian serves as an Associate Professor of Genomics and Precision Medicine at The George Washington University School of Medicine and Health Sciences. He has held this position since 2009, contributing to the field of genomics in Washington, D.C. His role involves supervising a multidisciplinary team that includes professionals from Neurosurgery, Neurology, Oncology, and Research departments, facilitating collaborative efforts in medical research and education.
Education and Expertise
Javad Nazarian completed his Bachelor of Science in Biochemistry at Florida State University from 1996 to 1998. He furthered his education at The George Washington University, obtaining a Master of Science in Biology from 1998 to 2000. He then pursued a Doctor of Philosophy in Genetics from 2000 to 2005 at the same institution. His academic background provides a strong foundation for his research in genomics and precision medicine.
Research Focus and Methodologies
Nazarian employs both in-vivo and in-vitro cancer models to investigate tumor cells within controlled microenvironments, which are essential for preclinical testing. His research utilizes advanced technologies to generate comprehensive profiles of childhood brain tumors, including genome, proteome, microRNA, and mRNA analyses. This approach aims to enhance understanding and treatment of high-grade childhood cancers.
Biobank Development for Childhood Cancer Research
Javad Nazarian has built one of the world’s largest biobanks dedicated to Diffuse Intrinsic Pontine Glioma (DIPG) and other high-grade childhood cancer tissue samples. This biobank plays a critical role in supporting research efforts aimed at improving treatment options and outcomes for pediatric patients with aggressive brain tumors.